Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613801 | 0.90 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL222367 | 0.90 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL222368 | 0.90 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL16292529 | 0.87 | ALOX5 (0.39) | — | |
| SCHEMBL343584 | 0.85 | ALOX5 (0.35) | — | |
| SCHEMBL343583 | 0.85 | ALOX5 (0.35) | — | |
| SCHEMBL345654 | 0.84 | GABRA5 (0.38) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL27776378 | 0.83 | ALOX5 (0.39) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL1222696 | 0.81 | SLC6A2 (0.36) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL27166484 | 0.81 | ITGB3 (0.41) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3026049-B1 | METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE | DONG A ST CO LTD (KR) | 2021-09-22 | — | — | EP | disclosed |
| US-9845308-B2 | Isoindoline inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9771348-B2 | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate | DONG-A ST CO., LTD (KR) | 2017-09-26 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-7691881-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2008156715-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-11-27 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-5254560-A | Treating disorders involving hyperactivity of adrenergic system in lower urinary tract | SYNTHELABO (FR) | 1993-10-19 | — | — | US | disclosed |
| US-5246939-A | Antiadrenergic systems for lower urinary apparatus | SYNTHELABO (FR) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | GABRA5 1448/4885GABRB2 3719/4885SLC6A1 2531/4885 |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | GABRA5 195/4885GABRB2 315/4885SLC6A1 893/4885 |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | GABRA5 153/4885GABRB2 319/4885SLC6A1 1482/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | GABRA5 165/4885GABRB2 385/4885SLC6A1 1048/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | GABRA5 893/4885GABRB2 1606/4885SLC6A1 751/4885 |
| US-20080293767-A1 | 1-Isopropyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide Derivatives Having 5-Ht4 Receptor Agonistic Activity | HRH4, HRH2, GPR4 | GABRA5 380/4885GABRB2 573/4885SLC6A1 2540/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | GABRA5 1458/4885GABRB2 3729/4885SLC6A1 2540/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GABRA5 4175/4885GABRB2 3750/4885SLC6A1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.